Claudia De Lorenzo

Title: Claudia De Lorenzo: Innovator in Antibody Therapy

Introduction

Claudia De Lorenzo is a prominent inventor based in Napoli, Italy. She has made significant contributions to the field of biotechnology, particularly in the development of human mini-antibodies for therapeutic applications. With a total of two patents to her name, her work focuses on innovative solutions for cancer treatment.

Latest Patents

Claudia's latest patents include a groundbreaking invention titled "Human mini-antibody cytotoxic for tumor cells which express the ERBB2 receptor." This invention refers to a fully human mini-antibody, known as Erbicin, which is specific for the ErbB2 receptor and exhibits pharmacological, particularly anti-tumor, activity. The mini-antibody has been developed from a larger phage display library of human synthetic scFv through a process of affinity selection on live cells expressing various levels of ErbB2. The patent also encompasses the DNA and amino acid sequences of the antibody, the procedure for isolating it, and its therapeutic applications.

Career Highlights

Throughout her career, Claudia has worked with notable companies in the biotechnology sector, including Biotechnol S.a. and Biotecnol S.a. Her expertise in antibody development has positioned her as a key figure in the advancement of cancer therapies.

Collaborations

Claudia has collaborated with esteemed colleagues such as Giuseppe D'Alessio and Renata Piccoli. These partnerships have further enriched her research and contributed to her innovative projects.

Conclusion

Claudia De Lorenzo's work in the field of biotechnology, particularly her development of the Erbicin mini-antibody, showcases her commitment to advancing cancer treatment. Her contributions are paving the way for new therapeutic options in the fight against tumors.